Pharmacokinetic interactions in different combinations of specific pulmonary arterial hypertension treatment

Introduction: Combination therapy of the phosphodiesterase-type 5 inhibitors (PDE-5I) sildenafil (SIL) or tadalafil (TAD) and endothelin receptor antagonists (ERA) bosentan (BOS), ambrisentan (AMB), or macitentan (MAC) may cause mutual interactions in patients with pulmonary arterial hypertension (PAH). Aim of this study was to compare plasma concentrations in PAH patients according to different combination treatments and to identify combinations that cause relevant interactions.